Induction of COX-2 Expression by the Endocannabinoid Derivative R(+)-Methanandamide

  • Burkhard Hinz
  • Robert Ramer
  • Kay Brune
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 525)


Cannabinoids produce a broad array of potential therapeutical effects, including the reduction of nausea in cancer and AIDS patients undergoing chemotherapy [1]. In recent years, two G1 protein-coupled cannabinoid receptors, CB1 and CB2, have been identified and cloned. Whereas the CB2 receptor is preferentially expressed in the central nervous system [2], the CB2 receptor has been described as the predominant form expressed in peripheral immune cells [3]. The discovery of specific cannabinoid receptors was followed by the identification of two endogenous arachidonic acid derivatives, anandamide (N-arachidonylethanolamide) and 2-arachidonylglycerol, which exhibit specific binding affinity to cannabinoid receptors [4, 5]. However, emerging evidence suggests that various cannabinoid actions are mediated via cannabinoid receptor-independent pathways, comprising activation of mitogen-activated protein kinases (MAPKs) [6, 7], alteration of intracellular calcium [8] and cAMP levels [9, 10], inhibition of cytokine expression [11] and induction of histamine release [12].


Peripheral Immune Cell Specific Binding Affinity Arachidonic Acid Mobilization Brain Prostaglandin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McCabe M, Smith FP, MacDonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988; 6:243–246.PubMedCrossRefGoogle Scholar
  2. 2.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TL Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561–564.PubMedCrossRefGoogle Scholar
  3. 3.
    Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993; 90:7656–7660.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee M, Yang KH, Kaminski NE. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 1995; 275:529–536.PubMedGoogle Scholar
  6. 6.
    Liu J, Gao B, Mirshani F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346:835–840.PubMedCrossRefGoogle Scholar
  7. 7.
    Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M, Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 1998; 425:419–425.PubMedCrossRefGoogle Scholar
  8. 8.
    Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor-and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 1992; 42:838–845.PubMedGoogle Scholar
  9. 9.
    Heindel JJ, Keith WB. Specific inhibition of FSH-stimulated cAMP accumulation by Δ9-tetrahydrocannabinol in cultures of rat Sertoli cells. Toxicol Appl Pharmacol 1989; 101:124–134.PubMedCrossRefGoogle Scholar
  10. 10.
    Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 1999; 11:691–699.PubMedCrossRefGoogle Scholar
  11. 11.
    Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29:58–69.PubMedCrossRefGoogle Scholar
  12. 12.
    Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 2001; 1538:252–259.PubMedCrossRefGoogle Scholar
  13. 13.
    Shivachar AC, Martin BR, Ellis EF. Anandamide-and Δ9-tetrahydrocannabinolevoked arachidonic acid mobilization and blockade by SRI 41716A [N-(Piperidin-l-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methy1-1H-pyrazole-3-carboximide hydrochloride]. Biochem Pharmacol 1996; 51:669–676.PubMedCrossRefGoogle Scholar
  14. 14.
    Reichman M, Nen W, Hokin LE. Δ9-Tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices. Mol Pharmacol 1988; 34:823–828.PubMedGoogle Scholar
  15. 15.
    Hunter SA, Burstein SH. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 1997; 60:1563–1573.PubMedCrossRefGoogle Scholar
  16. 16.
    Bhattacharya SK. Δ9-Tetrahydrocannabinol (THC) increases brain prostaglandins in the rat. Psychopharmacology 1986; 90:499–502.PubMedCrossRefGoogle Scholar
  17. 17.
    Hunter SA, Audette CA, Burstein S. Elevation of brain prostaglandin E2 levels in rodents by Δ1-tetrahydrocannabinol. Prost Leukot Essent Fatty Acids 1991; 43:185–190.CrossRefGoogle Scholar
  18. 18.
    Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J Neurosci 1998; 18:5322–5332.PubMedGoogle Scholar
  19. 19.
    Abadji V, Lin S, Tana G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37:1889–1893.PubMedCrossRefGoogle Scholar
  20. 20.
    Hinz B, Brune K, Pahl A. Prostaglandin E2 up-regulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2000; 272:744–748.PubMedCrossRefGoogle Scholar
  21. 21.
    Hinz B, Brune K, Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E2 and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000; 278:790–796.PubMedCrossRefGoogle Scholar
  22. 22.
    Ellis EF, Moore SF, Willoughby KA. Anandamide and Δ9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 1995; 269:H1859–H1864.PubMedGoogle Scholar
  23. 23.
    Burstein SH, Hull K, Hunter SA, Shilstone J. Immunization against prostaglandins reduces Δ1-tetrahydrocannabinol-induced catalepsy in mice. Mol Pharmacol 1989; 35:6–9.PubMedGoogle Scholar
  24. 24.
    Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991; 48:507–515.PubMedCrossRefGoogle Scholar
  25. 25.
    Yamaguchi T, Shoyama Y, Watanabe S, Yamamoto T. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. Brain Res 2001; 889:149–154.PubMedCrossRefGoogle Scholar
  26. 26.
    Pate DW, Jarvinen K, Urtti A, Jarho P, Fich M, Mahadevan V, Jarvinen T. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci 1996; 58:1849–1860.PubMedCrossRefGoogle Scholar
  27. 27.
    Green K, Kearse EC, McIntyre OL. Interaction between Δ9-tetrahydrocannabinol and indomethacin. Ophthalmic Res 2001; 33:217–220.PubMedCrossRefGoogle Scholar
  28. 28.
    Hinz B, Brune K. Cyclooxygenase-2-Ten years later. J Pharmacol Exp Ther 2002; 300:367–375.PubMedCrossRefGoogle Scholar
  29. 29.
    Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995; 83:493–501.PubMedCrossRefGoogle Scholar
  30. 30.
    Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Δ9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436:6–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997; 272:21181–21186.PubMedCrossRefGoogle Scholar
  32. 32.
    Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 2000; 275:33744–33749.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Burkhard Hinz
    • 1
  • Robert Ramer
  • Kay Brune
  1. 1.Department of Experimental and Clinical Pharmacology and ToxicologyFriedrich Alexander University Erlangen-NurembergErlangenGermany

Personalised recommendations